139 related articles for article (PubMed ID: 34296508)
1. Limitations of VS38c labeling in the detection of plasma cell myeloma by flow cytometry.
Czeti Á; Szalóki G; Varga G; Szita VR; Komlósi ZI; Takács F; Márk Á; Timár B; Matolcsy A; Barna G
Cytometry A; 2022 Feb; 101(2):159-166. PubMed ID: 34296508
[TBL] [Abstract][Full Text] [Related]
2. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
Manasanch EE; Salem DA; Yuan CM; Tageja N; Bhutani M; Kwok M; Kazandjian D; Carter G; Steinberg SM; Zuchlinski D; Mulquin M; Calvo K; Maric I; Roschewski M; Korde N; Braylan R; Landgren O; Stetler-Stevenson M
Leuk Lymphoma; 2015 May; 56(5):1416-24. PubMed ID: 25263319
[TBL] [Abstract][Full Text] [Related]
4. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.
Broijl A; de Jong ACM; van Duin M; Sonneveld P; Kühnau J; van der Velden VHJ
Am J Clin Pathol; 2022 Apr; 157(4):494-497. PubMed ID: 34643211
[TBL] [Abstract][Full Text] [Related]
5. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
[TBL] [Abstract][Full Text] [Related]
6. VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era.
Mizuta S; Kawata T; Kawabata H; Yamane N; Mononobe S; Komai T; Koba Y; Ukyo N; Tamekane A; Watanabe M
Int J Hematol; 2019 Sep; 110(3):322-330. PubMed ID: 31183814
[TBL] [Abstract][Full Text] [Related]
7. FLOCK cluster analysis of plasma cell flow cytometry data predicts bone marrow involvement by plasma cell neoplasia.
Dorfman DM; LaPlante CD; Li B
Leuk Res; 2016 Sep; 48():40-5. PubMed ID: 27479652
[TBL] [Abstract][Full Text] [Related]
8. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
Orfäo A; García-Sanz R; López-Berges MC; Belén Vidriales M; González M; Caballero MD; San Miguel JF
Cytometry; 1994 Dec; 17(4):332-9. PubMed ID: 7533074
[TBL] [Abstract][Full Text] [Related]
9. [Bone marrow immunophenotyping for the diagnosis of multiple myeloma: practical aspects].
Kurtova AV; Sivachenko EB; Utkina LA; Slobodniuk KIu; Stepanova NV; Iakubovich MA; Moiseev SI; Zueva EE
Klin Lab Diagn; 2008 Jan; (1):17-20. PubMed ID: 18314774
[TBL] [Abstract][Full Text] [Related]
10. [Multiple myeloma immunophenotyping: method validation].
Vergnolle I; Rieu JB; Avet-Loiseau H; Corre J; Vergez F
Ann Biol Clin (Paris); 2019 Apr; 77(2):197-217. PubMed ID: 30998199
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M
Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038
[TBL] [Abstract][Full Text] [Related]
12. [Optimizing plasma cell content in bone marrow aspirates].
Hoffmann T; Favre G; Gratwohl A; Passweg J; Mathys S; Borel J; Speck B; Tichelli A
Schweiz Med Wochenschr; 1998 Oct; 128(42):1611-3. PubMed ID: 9824893
[TBL] [Abstract][Full Text] [Related]
13. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
Yuan CM; Stetler-Stevenson M
Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell morphology in multiple myeloma and related disorders.
Ribourtout B; Zandecki M
Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
17. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
18. Polychromatic flow cytometry is more sensitive than microscopy in detecting small monoclonal plasma cell populations.
Tran DN; Smith SA; Brown DA; Parker AJ; Joseph JE; Armstrong N; Sewell WA
Cytometry B Clin Cytom; 2017 Mar; 92(2):136-144. PubMed ID: 27416483
[TBL] [Abstract][Full Text] [Related]
19. An alternative processing approach to increase CD138 intensity in flow cytometric analysis of plasma cells.
Kumar D; Kiran FNU; Wheeler A; Dellamano R; Hammer RD
Cytometry B Clin Cytom; 2024 Mar; 106(2):113-116. PubMed ID: 38010113
[TBL] [Abstract][Full Text] [Related]
20. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
